[{"id":"f0daf336-adfd-4a5d-9be4-7e41ac19d14d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05200559","created_at":"2022-01-20T14:53:46.428Z","updated_at":"2024-07-02T16:35:29.800Z","phase":"Phase 1/2","brief_title":"T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors","source_id_and_acronym":"NCT05200559","lead_sponsor":"Haider Mahdi","biomarkers":" MSI • CD4 • IL2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-11-09"},{"id":"06f2e6a8-bdd2-4a87-bef8-65924c69c48b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855253","created_at":"2021-04-22T20:53:39.288Z","updated_at":"2024-07-02T16:35:43.683Z","phase":"Phase 1/2","brief_title":"Study of E7777 Prior to Kymriah for R/R DLBCL","source_id_and_acronym":"NCT04855253","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-07-07"},{"id":"2206fad9-2403-4d16-b774-a54c873db7db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01871727","created_at":"2021-01-18T08:23:02.004Z","updated_at":"2024-07-02T16:35:59.275Z","phase":"Phase 3","brief_title":"A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma","source_id_and_acronym":"NCT01871727","lead_sponsor":"Eisai Inc.","biomarkers":" IL2RA • IL2 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • IL2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 05/30/2013","start_date":" 05/30/2013","primary_txt":" Primary completion: 12/06/2021","primary_completion_date":" 12/06/2021","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2022-12-12"},{"id":"5b6436a7-560a-4215-a007-3fdd787d2b36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676778","created_at":"2021-07-15T17:53:07.245Z","updated_at":"2024-07-02T16:36:27.892Z","phase":"Phase 2","brief_title":"Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma","source_id_and_acronym":"NCT02676778","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 04/26/2019","primary_completion_date":" 04/26/2019","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2021-07-15"}]